مقایسه افسردگی در افراد وابسته و غیر وابسته به کتامین، نیتروس اکساید و کوکائین

•   آرشیو : نسخه زمستان1401 - جلد دوم
•   کد پذیرش : 11968
•   موضوع : روانشناسی بالینی
• نویسنده/گان : | حسین هاشمی شیری، سحر میرزاده داریونی
•   زبان : فارسی
•   نوع مقاله : پژوهشی
•   چکیده مقاله به فارسی : زمینه و اهداف: کتامین، نیتروس اکساید و کوکائین سه داروی پرکاربرد در بیهوشی هستند که اخیراً اعتیاد به آنها سازمان¬های بهداشتی را با نگرانی مواجه کرده است. افرادی که به این داروها اعتیاد دارند ممکن است در خطر عوامل متعددی باشند، یکی از این عوامل ریسک مبتلا شدن به افسردگی است بنابراین هدف از انجام پژوهش حاضر مقایسه افسردگی در افراد وابسته و غیر وابسته به این داروها بود.
  مواد و روش ها: طرح پژوهش از نوع توصیفی مقایسه ای است. 240 نفر که در تابستان 1401 در شهر شیراز زندگی می کردند با روش گلوله برفی و در دسترس در چهار گروه نمونه گیری شدند (وابسته به کتامین، کوکائین، نیتروس اکساید و بدون وابستگی). پرسشنامه افسردگی بک بین گروه ها توزیع شد و داده ها جمع‌آوری شدند و سپس توسط نرم‌افزار SPSS26 مورد ارزیابی قرار گرفتند. برای بررسی نرمال بودن داده¬ها از آزمون شاپیرو-ویلک و از آزمون پارامتری تی مستقل برای مقایسه گروه بدون وابستگی با سایر گروه‌ها استفاده شد.
  یافته ها: تفاوت میانگین بین گروه بدون وابستگی و هر یک از گروه های وابسته به کوکائین، کتامین و نیتروس اکساید به ترتیب 6/1- (001/0p=)، 41667/1+ (000/0p=) و 41677/0- (392/0p=) به دست آمد.
  نتیجه گیری: نتایج نشان داد که گروه وابسته به کتامین به‌طور معناداری افسردگی کمتری نسبت به افراد غیر وابسته داشتند همچنین افراد وابسته به کوکائین به‌طور معناداری افسردگی بیشتری نسبت به افراد غیر وابسته داشتند و تفاوت معناداری بین افراد وابسته به نیتروس اکساید و افراد غیر وابسته یافت نشد؛ بنابراین متخصصان حوزه اعتیاد می توانند این داده ها را در اقدامات و تصمیمات خود مدنظر قرار دهند.
•   لیست منابع : [1] Fukumoto K, Iijima M, Chaki S. The Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN. Neuropsychopharmacology 2016; 41(4): 1046-56. doi: 10.1038/npp.2015.233.
  [2] Andrew F. Leuchter, Ian A. Cook, Aimee M. Hunter, Alexander S. Korb. A new paradigm for the prediction of antidepressant treatment response. Dialogues in Clinical Neuroscience 2009; 11(4): 435-446.
  [3] Michele F, Eugenio A, Liliana DO, Giulio P. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs?. Expert Opinion on Pharmacotherapy 2011; 12(18): 2817-2831.
  [4] Ersche KD, Lim TV, Murley AG, Rua C, Vaghi MM, White TL, Williams GB, Robbins TW. Reduced Glutamate Turnover in the Putamen Is Linked With Automatic Habits in Human Cocaine Addiction. Biological psychiatry 2021. 89(10): 970–979. https://doi.org/10.1016/j.biopsych.2020.12.009
  [5] Moustafa AA, Tindle R, Cashel S, Denise P, Enas M, Eid AH. Bidirectional relationship between heroin addiction and depression: Behavioural and neural studies. Curr Psychol 2022; 41: 5195–5211. https://doi.org/10.1007/s12144-020-01032-4
  [6] Van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf 2022; 21(1): 83-94.
  [7] Pribish A, Wood N, Kalava A. A Review of Nonanesthetic Uses of Ketamine. Anesthesiology research and practice 2020; 5798285. https://doi.org/10.1155/2020/5798285
  [8] Alqaysum ZA, Hakami AH, Gussadi AM, Alhashem. Ketamine versus standard opioid treatment for acute pain in the emergency department:systematic review and meta-analysis. Ann Med Health Sci Res 2021; 11(1): 1178-1182.
  [9] Bell R, Eccleston C, Kalso EA. Ketamine as an adjuvant to opioids for cancer pain. The Cochrane database of systematic reviews 2017; 6(6): CD003351. https://doi.org/10.1002/14651858.CD003351.pub3
  [10] Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). Molecular psychiatry 2020; 25(7): 1592–1603. https://doi.org/10.1038/s41380-018-0256-5
  [11] Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug design, development and therapy 2019; 13: 3051–3067. https://doi.org/10.2147/DDDT.S221437
  [12] Feder A, Rutter SB, Schiller D, Charney DS. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Advances in pharmacology (San Diego, Calif.) 2020; 89: 261–286. https://doi.org/10.1016/bs.apha.2020.05.004
  [13] Kryst J, Kawalec P, Mitoraj AM, Pilc A, Lasoń W, Brzostek T. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacological reports 2020; 72(3): 543–562. https://doi.org/10.1007/s43440-020-00097-z
  [14] Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Frontiers in psychiatry 2018; 9: 277. https://doi.org/10.3389/fpsyt.2018.00277
  [15] FDA (Food and Drug Administration). FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic 2019. [cited 2021 Mar 31]. Available form:https://www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified
  [16] EMA. European Medicines Agency (EMA). Spravato 2020. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/spravato18
  [17] EMCDDA. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European Drug Report 2019: trends and Developments, Publications Office of the European Union, Luxembourg 2019. Available form:https://www.emcdda.europa.eu/system/files/publications/11364/20191724_TDAT19001ENN_PDF. pdf19.
  [18] Johnston LD, Miech RA, O’Malley PM, Bachman JG, Schulenberg JE, Patrick ME. Monitoring the future. National survey results on drug use, 1975–2019. 2019 Overview. Key findings on adolescent drug use 2020. Available form: https:// cdn.ymaws.com/www.fadaa.org/resource/resmgr/files/resource_ center/mtf-overview2019.pdf
  [19] Li JH, Vicknasingam B, Cheung YW, Zhou W, Nurhidayat AW, Jarlais DC, Schottenfeld R. To use or not to use: an update on licit and illicit ketamine use. Substance abuse and rehabilitation 2011; 2: 11–20. https://doi.org/10.2147/SAR.S15458
  [20] Huizink AC. Trends and associated risks in adolescent substance use: E-cigarette use and nitrous oxide use. Current opinion in psychology 2022; 45: 101312. https://doi.org/10.1016/j.copsyc.2022.101312
  [21] van Amsterdam JG, Nabben T, van den Brink W. Increasing recreational nitrous oxide use: Should we worry? A narrative review. Journal of psychopharmacology (Oxford, England) 2022; 36(8): 943–950. https://doi.org/10.1177/02698811221082442
  [22] Kalivas PW. Cocaine and amphetamine-like psychostimulants: neurocircuitry and glutamate neuroplasticity. Dialogues in clinical neuroscience 2007, 9(4): 389–397. https://doi.org/10.31887/DCNS.2007.9.4/pkalivas
  [23] Ledesma JC, Manzanedo C, Aguilar MA. Cannabidiol prevents several of the behavioral alterations related to cocaine addiction in mice. Progress in neuro-psychopharmacology & biological psychiatry 2021; 111: 110390. https://doi.org/10.1016/j.pnpbp.2021.110390
  [24] SAMHSA-Substance Abuse Mental Health Services Administration, 2018. Results fromthe 2017 National Survey on Drug Use and Health: Summary of National Findings.Rockville. MD. USA, DHHS.
  [25] Torres-Castaño A, Rivero-Santana A, Perestelo-Pérez L, Duarte-Díaz A, Toledo-Chávarri A, Ramos-García V, Álvarez-Pérez Y, Cudeiro-Mazaira J, Padrón-González I, Serrano-Pérez P. Transcranial Magnetic Stimulation for the Treatment of Cocaine Addiction: A Systematic Review. Journal of clinical medicine 2021; 10(23): 5595. https://doi.org/10.3390/jcm10235595
  [26] Volkow ND, Fowler JS, Wang GJ, Swanson JM. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Molecular psychiatry 2004; 9(6): 557–569. https://doi.org/10.1038/sj.mp.4001507
  [27] Moreno-López L, Catena A, Fernández-Serrano MJ, Delgado-Rico E, Stamatakis EA, Pérez-García M, Verdejo-García A. Trait impulsivity and prefrontal gray matter reductions in cocaine dependent individuals. Drug and alcohol dependence 2012; 125(3): 208–214. https://doi.org/10.1016/j.drugalcdep.2012.02.012
  [28] Matochik JA, London ED, Eldreth DA, Cadet JL, Bolla KI. Frontal cortical tissue composition in abstinent cocaine abusers: a magnetic resonance imaging study. NeuroImage 2003; 19(3): 1095–1102. https://doi.org/10.1016/s1053-8119(03)00244-1
  [29] Jasinska AJ, Chen BT, Bonci A, Stein EA. Dorsal medial prefrontal cortex (MPFC) circuitry in rodent models of cocaine use: implications for drug addiction therapies. Addiction biology 2015; 20(2): 215–226. https://doi.org/10.1111/adb.12132
  [30] Chen BT, Yau HJ, Hatch C, Kusumoto-Yoshida I, Cho SL, Hopf FW, Bonci A. Rescuing cocaine-induced prefrontal cortex hypoactivity prevents compulsive cocaine seeking. Nature 2013; 496(7445): 359–362. https://doi.org/10.1038/nature12024
  [31] Terraneo A, Leggio L, Saladini M, Ermani M, Bonci A, Gallimberti L. Transcranial magnetic stimulation of dorsolateral prefrontal cortex reduces cocaine use: A pilot study. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 2016; 26(1): 37–44. https://doi.org/10.1016/j.euroneuro.2015.11.011
  [32] Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR. The dopamine theory of addiction: 40 years of highs and lows. Nature reviews. Neuroscience 2015; 16(5): 305–312. https://doi.org/10.1038/nrn3939
  [33] Stefan-Dabson K, Mohammadkhani P, Massah-Choulabi O. Psychometrics Characteristic of Beck Depression Inventory-II in Patients with Magor Depressive Disorder. jrehab. 2007; 8 :82-0
  URL: http://rehabilitationj.uswr.ac.ir/article-1-135-en.html
  [34] Price RB, Kissel N, Baumeister A, Rohac R, Woody ML, Ballard ED, et al. International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators. Mol Psychiatry 2022. https://doi.org/10.1038/s41380-022-01757-7
  [35] Ponton E, Turecki G, Nagy C. Sex Differences in the Behavioral, Molecular, and Structural Effects of Ketamine Treatment in Depression, International Journal of Neuropsychopharmacology 2022; 25(1): 75–84. https://doi.org/10.1093/ijnp/pyab082
  [36] Ekstrand J, Fattah C, Persson M, Cheng T, Nordanskog P, Åkeson J, Tingström A, Lindström MB, Nordenskjöld A, Movahed Rad P, Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT), International Journal of Neuropsychopharmacology 2022; 25(5): 339–349. https://doi.org/10.1093/ijnp/pyab088
  [37] Dwyer JB, Landeros-Weisenberger A, Johnson JA, Tobon AL, Flores JM, Nasir M, Couloures K, Sanacora G, Bloch MH. Efficacy of Intravenous Ketamine in Adolescent Treatment-Resistant Depression: A Randomized Midazolam-Controlled Trial. Tools to Address Children’s Mental Health 2022; 2(20): 241-251. https://doi.org/10.1176/appi.focus.22020004
  [38] Leal B, Vila-Chã D, Garcia S, Pinto I, Mateiro R, Avelino M, . . . Salgado J. Nitrous Oxide in Treatment Resistant Major Depression: Should We Laugh About It?. European Psychiatry 2022; 65(S1): S716-S716. doi:10.1192/j.eurpsy.2022.1847
  [39] Nagele P, Duma A, Kopec M, Gebara MA, Parsoei A, Walker M, Janski A, Panagopoulos VN, Cristancho P, Miller JP, Zorumski CF, Charles R. Conway,Nitrous Oxide for Treatment-Resistant Major Depression: A Proof-of-Concept Trial. Biological Psychiatry2015; 78(1): 10-18
  [40] Luque B, García V, Tabernero C. "Depression and Cognitive Impairment in a Spanish Sample of Psychoactive Substance Users Receiving Mental Health Care" Healthcare 2022; 10(5): 887. https://doi.org/10.3390/healthcare10050887.
•   کلمات کلیدی به فارسی : اعتیاد، کتامین، نیتروس اکساید، کوکائین، افسردگی.
•   چکیده مقاله به انگلیسی : Aims and background: Ketamine, nitrous oxide, and cocaine are three commonly used drugs in anesthesia, and their addiction has recently worried health organizations. People who are addicted to these drugs may be at risk of several factors, one of these factors is the risk of depression, so the purpose of this research was to compare depression in people dependent and non-dependent on these drugs.
  Materials and methods: The research design is descriptive-comparative. 240 people who lived in Shiraz city in the summer of 1401 were sampled in four groups (addicted to ketamine, cocaine, nitrous oxide and non-addicted) by using the Snowball and Available method. Beck's depression questionnaire was distributed among the groups and the data was collected and then evaluated by SPSS26 software. To check the normality of the data, the Shapiro-Wilk test and the independent parametric T-test were used to compare the independent group with other groups.
  Results: The average difference between the cocaine, ketamine and nitrous oxide group with the non-addicted group was -1.6 (p=0.001>0.05), +1.41667 (p=0.000<0.05) and -0.41677 (0.05 Conclusion: The results showed that the ketamine-dependent group had significantly less depression than the non-dependent group, and the cocaine-dependent group had significantly more depression than the non-dependent group, and significant difference between nitrous oxide-dependent group and non-dependent group not found. Therefore, experts in the field of addiction can consider these data in their actions and decisions
•   کلمات کلیدی به انگلیسی : addiction, ketamine, nitrous oxide, cocaine, depression
•  صفحات : 41-50
•   دانلود فایل ( 1.01 MB )